Adaptyv Biosystems vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 44)
Adaptyv Biosystems logo

Adaptyv Biosystems

EmergingHealthcare

General

Lausanne Switzerland automated cloud lab for AI protein engineering at $11.2M total ($8M ACE Ventures seed 2025); improved protein success rate from 2.

AI VisibilityBeta
Overall Score
C44
Category Rank
#328 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
39
Gemini
48

About

Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

44
Overall Score
88
#328
Category Rank
#3
76
AI Consensus
78
stable
Trend
stable
49
ChatGPT
83
39
Perplexity
87
48
Gemini
85
45
Claude
90
47
Grok
92

Key Details

Category
General
AI Drug Discovery
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.